Mylan announced the launch of Lamivudine Tablets, the generic version of GlaxoSmithKline’s Epivir-HBV.

Epivir-HBV is a nucleoside analogue (reverse transcriptase inhibitor) indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of HBV replication and active liver inflammation. Intracellularly, lamivudine is phosphorylated to its active 5′-triphosphate metabolite, lamivudine triphosphate, 3TC-TP. 3TC-TP inhibits the RNA- and DNA-dependent polymerase activities of HBV reverse transcriptase via DNA chain termination after incorporation of the nucleotide analogue into viral DNA.

RELATED: Hep B Screening Urged for Those Undergoing Chemo, Immune Tx

Lamivudine Tablets are available as a 100mg strength.

For more information call (800) RX-MYLAN or visit